Antibody-directed, effector cell-mediated tumor destruction

Hematology/Oncology Clinics of North America

Volumn 15, Issue 4, 2001, Pages 703-721

  Sondel, Paul M ^a   Hank, Jacquelyn A ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; MONOCLONAL ANTIBODY; RECOMBINANT CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CELL DESTRUCTION; CELL FUNCTION; CELLULAR IMMUNITY; CONTROLLED STUDY; EFFECTOR CELL; GENE REARRANGEMENT; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0034793479     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70243-4     Document Type: Article

References (63)

1. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma
2. Phase IB trial of chimeric anti-GD2 antibody plus interleukin-2 for melanoma patients
3. Antibody-cytokine fusion protein (hu14.18-IL-2) retains biologic activity in human serum following in vivo administration for treatment of melanoma
4. T cell mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy
5. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
6. Human cancer detection and immunotherapy with conjugated and nonconjugated monoclonal antibodies
7. Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: Addition of cytosine arabinoside to the pretransplant conditioning prevents rejection
8. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission
9. Induction of Ab3 and Ab3′ antibody is associated with longterm survival after anti-GD2 antibody therapy of stage 4 neuroblastoma
10. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: A phase II study
11. Tumor associated antigens (TAA) mimicry and immunotherapy of malignant diseases: From anti-idiotypic antibodies to peptide mimics
12. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotypic antibody mimicking disialogan-glioside GD2
13. Clinical applications of monoclonal antibodies for patients with leukemia and lymphoma
14. Phase I/IB trial of murine monoclonal anti GD2 antibody 14.C2a plus IL2 in children with refractory neuroblastoma: A report of the Children's Cancer Group
15. Specific ELISA systems for quantitation of antibody-cytokine fusicn proteins
16. High level expression of chimeric antibodies using adapted cDNA variable region cassettes
17. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases
18. Antibody-targeted interleukin 2 stimulates the T-cell killing of autologous tumor cells
19. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins
20. The CAMPATH-1 antigen (CDw52)
21. A phase I study of human-mouse chimeric anti-ganglioside GD2 antibody ch14.18 in patients with neuroblastoma
22. Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant disease
23. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin-2
24. Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2
25. 2 antibody plus interleukin-2 induces antibody dependent cellular cytotoxicity against neuroblastoma detected in vitro
26. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside-GD2/interleukin-2 fusion protein (ch14.18-IL2)
27. Graft-versus-leukemia reactions after bone marrow transplantation
28. Monoclonal antibody blockade of the epidermal growth factor receptor in cancer therapy
29. Towards a network theory of the immune system
30. Antibody-based immunotherapies for cancer
31. Monoclonal antibody therapy of cancer
32. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 monoclonal antibody) and interleukin-2
33. Targeted interleukin-2 therapy of spontaneous neuroblastoma metastases to bone marrow
34. Biologic therapy with interleukin-2
35. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin lymphoma
36. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
37. Anti-idiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse anti-idiotypic monoclonal antibody MK2-23
38. Disialoganglioside GD2 on human neuroblastoma cells: Target antigen for monoclonal antibody mediated cytolysis and suppression of tumor growth
39. D2 antibody 14.18
40. Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies
41. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma
42. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
43. A phase I study of chimeric human/murine anti-ganglioside GD2 monoclonal antibody (ch14.18) with GM-CSF in children with neuroblastoma immediately post hematopoietic stem cell transplantation: A Children's Cancer Group study
44. Targeted therapy for high risk AML
45. Immunocytokines: A new approach to immunotherapy of melanoma
46. Recombinant antibody fusion proteins for cancer immunotherapy
47. Monoclonal antibody therapy for resected Duke C colorectal cancer: Seven-year outcome of a multicenter randomized trial
48. Randomised trial of monoclonal antibody for adjuvant therapy of resected Duke C colorectal carcinoma
49. Tumor immunity in perforin-deficient mice: A role for CD95(Fas/APO-1)
50. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma
51. Destruction of autologous human lymphocytes by IL2 activated cytotoxic cells
52. Cellular immunity and cytokines
53. Reengineered monoclonal antibodies step up to the plate in cancer studies
54. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydropetoxycyclophosphamide for marrow purging
55. Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: Experiments of nature continue to point the way
56. + natural killer cells after in vivo IL2 therapy: p70 expression does not alone predict the level of intermediate affinity IL2 binding
57. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: Predominant role for lymphocytes with increased expression of CD2 and Leu19 antigens but negative expression of CD16 antigens
58. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy
59. Combined use of a human mouse chimeric anti-GD2 (ch14.18) and GM-CSF in the treatment of refractory neuroblastoma
60. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch 14.18 in patients with refractory neuroblastoma and osteosarcoma